StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Anavex Life Sciences (AVXL) Reports Data from Review by Independent DSMB for U.S. Phase 2 Clinical Trial of ANAVEX2-73
July 31, 2019 7:26 AM
Anavex Life Sciences Corp. (NASDAQ: AVXL) today announced that the Independent Data Safety Monitoring Board (DSMB) for the Company's U.S ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
July 31, 2019 7:00 AM
Pre-Open Movers 07/29: (TYME) (MCC) (MYL) Higher; (LXRX) (ONDK) (CTB) (more...)
July 29, 2019 9:28 AM
Anavex Life Sciences (AVXL) Receives Positive Opinion for Orphan Designation from EMA for ANAVEX2-73 for Treatment of Rett Syndrome
July 29, 2019 7:11 AM
